Skip to content
Search

Latest Stories

NHS sets new record of three million cancer checks in 12 month

NHS cancer check has set a new record, despite pressures on hospitals due to Covid-19, the number of people being treated for the cancer remained higher than before the pandemic, revealed NHS.

Over the last 12 months almost three million people were referred for cancer checks which is up by over a tenth on the 2.4 million people referred before the pandemic.


“Even at the peak of the Omicron wave, referrals for suspected cancer were at 116 per cent of pre-pandemic levels with around 11,000 people getting checked every day over the last year,” said NHS.

In order to meet increasing demand for cancer checks, NHS services across the country are expanding their diagnostic capabilities through one stop shops for tests, mobile clinics and cancer symptom hotlines, ensuring people are diagnosed and treated as early as possible to give them a much better chance of beating the disease.

More than 30,000 people every month are being invited for lung cancer checks through NHS mobile trucks visiting at risk communities across the country, as part of the biggest programme to improve early lung cancer diagnosis in health service history.

In London, the first ‘Man Van’ programme, developed by The Royal Marsden NHS Foundation Trust, RM Partners West London Cancer Alliance, and The Institute of Cancer Research, London, is rolling out to provide free health checks for men and boost early diagnosis of prostate and other urological cancers.

The van, currently in New Addington, previously visited workplaces and churches in the South West London area, focusing on men of working age who often have worse prostate cancer outcomes than older men, and black men, who have roughly double the risk of developing prostate cancer and an increased risk of death once diagnosed. It is now open to the public and will be visiting various locations within West London.

At The Rotherham NHS Foundation Trust, they have introduced telephone triage for certain cancer referrals so that patients can speak to doctors sooner, as well as increasing the use of ‘straight-to-test’ pathways for lower gastrointestinal patients to get diagnosed as early as possible, and expanding one-stop-shop slots for patients referred under a breast cancer pathway, so patients can get all their tests in one trip.

NHS staff have gone to great lengths to maintain cancer treatment for patients and since March 2020, more than 4.7m have been referred and more than half a million people have started treatment.

Common symptoms of cancer include lumps or bumps and unexplained weight loss or fatigue.

Dame Cally Palmer, National Cancer Director for NHS England, said: “We are going further and faster than ever before in our ambitions to diagnose more cancers at an earlier stage so that we can save more lives.

“We have seen record numbers of people coming forward for checks in the last year, but we know there are still at least 30,000 who haven’t started treatment due to the pandemic, so it’s vital that we keep these referral rates high.

“While we know this can’t happen overnight, we’re investing in extra diagnostic and treatment capacity to meet increasing demand, with staff working hard to roll out initiatives from straight to test services, cancer symptom hotlines and innovative diagnostics, so that those who are coming forward for checks can be seen quickly and their cancer identified at an earlier stage”.

Responding to news that almost three million people - the highest on record - were referred for cancer checks over the last 12 months in England, Dr Layla McCay, director of policy at the NHS Confederation, said, “Health leaders and their teams have worked incredibly hard to recover services since the worst of Covid, carrying out almost three million checks for cancer over the past 12 months. The NHS has been encouraging people to come forward and has introduced new ways of bringing vital checks closer to people, through innovative schemes such as the use of mobile clinics.

“However, NHS leaders know there is a lot more to do with many people yet to receive a cancer diagnosis or begin treatment. This is why our members have been calling on the Government to be clear about the ongoing threat of Covid-related disruptions to services, the state the NHS is currently in with over 110,000 staff vacancies, and how long it will take for the health service to truly recover.

“Continued progress to accelerate cancer diagnoses and treatments must be assured for the years to come, through increased funding from central government and a long-term plan for boosting and supporting the NHS workforce, particularly where there are shortages in key specialist areas.”

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less